(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 22.77% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Esperion Therapeutics's revenue in 2026 is $303,802,000.On average, 11 Wall Street analysts forecast ESPR's revenue for 2026 to be $96,397,549,702, with the lowest ESPR revenue forecast at $78,953,090,704, and the highest ESPR revenue forecast at $143,132,061,001. On average, 8 Wall Street analysts forecast ESPR's revenue for 2027 to be $107,399,249,072, with the lowest ESPR revenue forecast at $66,072,352,718, and the highest ESPR revenue forecast at $148,099,799,222.
In 2028, ESPR is forecast to generate $139,828,204,301 in revenue, with the lowest revenue forecast at $97,929,946,333 and the highest revenue forecast at $193,911,525,654.